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Background: The use of doxycycline has been avoided before 8 years of age due to known dental staining caused
by tetracyclines, although doxycycline differs from classical tetracyclines in many ways. Doxycycline is still an im-
portant antimicrobial agent, but its dental safety is not well studied.
Objectives: To examine the state of permanent teeth after doxycycline exposure in children ,8 years of age.
Methods: Details of doxycycline treatment were collected from medical records. After the eruption of perman-
ent teeth the dental status was examined by an experienced paediatric dentist for detection of dental staining
and enamel hypoplasia. The resulting dental photographs were evaluated by a second independent experienced
paediatric dentist.
Results: The mean age of 38 study subjects at the time of doxycycline treatment was 4.7 years (range 0.6–7.9 years,
SD 2.3). The doxycycline dose was 10 mg/kg/day (varying from 8 to 10 mg/kg/day) for the first 2–3 days and
5 mg/kg/day (varying from 2.5 to 10 mg/kg/day) thereafter. The mean length of the treatment was 12.5 days
(SD 6.0) and ranged from 2 to 28 days. Tetracycline-like staining or enamel hypoplasia of developing teeth was
detected in none of the subjects.
Conclusions: Doxycycline treatment of small children does not seem to induce permanent tooth staining.
Introduction
Tetracycline treatment in young children during the rapid calcifica-
tion phase of teeth results in staining of permanent teeth, first
described in 1959.1 The rate of discolouration varies from 23% to
92%, depending on the duration of the exposure.2 This is why the
use of tetracyclines is contraindicated in young children.3
Doxycycline is a second-generation semi-synthetic tetracycline
and it differs from classical tetracyclines in several aspects, e.g. in
lower calcium-binding capacity.4 Doxycycline’s long half-life per-
mits once-daily dosing, penetrates the blood–brain barrier effect-
ively, is fully absorbed enterally and is well tolerated.5,6 There are
no reported cases of permanent dental staining possibly induced
by doxycycline in young children. However, it has been recom-
mended that the use of doxycycline be avoided in children aged
,8 years.
In our hospital, doxycycline has been used in the empirical
treatment of acute infection-related CNS symptoms mainly to
cover Borrelia burgdorferi7 and Mycoplasma pneumoniae.8 The aim
of this study was to evaluate the state of permanent teeth of chil-
dren treated with doxycycline before the age of 8 years.
Methods
The inclusion criteria were doxycycline exposure at the age of 0–7.9 years
and a minimum age of 8 years at the time of dental examination. These
age limits were selected based on the known dental mineralization timeline
of tooth development.9 We reviewed the medical records of 1132 children
hospitalized due to suspicion of CNS infection during 1994–2015 at the
Department of Paediatrics and Adolescent Medicine, Turku University
Hospital. The inclusion criteria were met by 56 children, of whom 39 agreed
to participate in the study.
Details of treatment were collected from medical records. Dental
examinations were performed by an experienced paediatric dentist
(M. N.). Dental developmental stage was noted. The focus of the clinical
examination was to detect tetracycline-like staining in the forms of dif-
fuse discoloured bands of tooth crowns and enamel hypoplasia. Teeth
were photographed using a mouth mirror from five perspectives with a
Canon 7D camera (Canon, Tokyo, Japan). Photographs were evaluated by
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a second experienced paediatric dentist (S. A.), blind to the results of
the first examiner.
Ethics
The study subjects and/or their parents gave informed consent. This study
was approved by the Ethics Committee of the Hospital District of Southwest
Finland (T7/2015).
Results
Reliable information on doxycycline treatment was found for 38 of
39 study subjects. Thirty-seven subjects had received one course
of doxycycline and 1 had received two courses. Twenty-four of the
study subjects (63%) were male (Table 1). The mean age at the
time of doxycycline treatment was 4.7 years (range 0.6–7.9 years,
SD 2.3). The mean length of the treatment was 12.5 days (range
2–28 days, SD 6.0). The doxycycline dose was exactly reported in
30 of 39 courses. The loading dose for the first 2–3 days was
10 mg/kg/day (varied from 8 to 10 mg/kg/day). The average dose
thereafter was 5 mg/kg/day (varied from 2.5 to 10 mg/kg/day).
Doxycycline was administered once or twice daily. The administra-
tion route was first intravenous and later oral in 18 (46%), only oral
in 12 (31%) and only intravenous in 9 (23%) courses. The indication
of doxycycline treatment was suspicion of CNS infection in 38/39
courses. In 28 cases (74%) the final diagnosis was CNS infection.
Of these, 18 (47%) met the criteria of encephalitis (persisting
neurological symptoms with abnormal findings in CSF, electroen-
cephalogram or brain MRI), 3 (8%) the criteria of meningitis (menin-
gismus and pleocytosis) and 7 (18%) the criteria of neuroborreliosis
(facial palsy with diagnostic Borrelia serology). The aetiology of CNS
symptoms in the remaining cases is shown in Table 1.
The mean follow-up time was 9.6 years (range 3.3–15.5 years,
SD 3.1) and the mean age at the dental examination was
14.2 years (range 8.3–22.6 years) (Table 1). Fourteen subjects
(37%) were at the phase of mixed dentition. Neither tetracycline-
like dental staining nor enamel hypoplasia was seen in permanent
teeth of the patients in the clinical examination or in the photo-
graphs (Tables 1 and 2).
Discussion
In this limited study population, doxycycline treatment of children
under 8 years did not induce staining of permanent teeth.
One-fifth of our subjects were aged ,2 years during the exposure,
i.e. in the calcification stage of the visible incisor teeth. Also, intra-
venous administration of doxycycline did not induce dental stain-
ing. Furthermore, in our series the doxycycline dose was high: a
loading dose of up to 10 mg/kg/day for 2–3 days, followed by a
dose of 5 mg/kg/day. A higher loading dose is routinely used to
achieve optimal doxycycline concentration from the beginning of
the treatment.8 In addition, the duration of treatment was long
(average 12.5 days).
In agreement with our observations, two previous studies found
no tetracycline-like tooth discolouration after doxycycline treat-
ment in young children. In one study oral doxycycline was used for
10 days with a daily dose of 2–4 mg/kg in 2- to 7-year-old children
with asthma,10 and in another study for 7 days with 2.3 mg/kg/day
for Rocky Mountain spotted fever in 0.2- to 7.9-year-old children.11
Including our study there are now 127 reported cases of children









borreliosis (other than neuroborreliosis) 3 (8)
status epilepticus and epileptic seizure 2 (5)
intracranial haemorrhage 1 (3)
other 4 (11)
Length of doxycycline treatment (days)a, mean (SD) 12.5 (6.0)
Age at dental examination (years), mean (SD) 14.2 (3.7)
Time between doxycycline exposure and dental examination (years), mean (SD) 9.6 (3.1)
Tetracycline-related dental findings, n (%)
tetracycline-like discolouration 0 (0)
enamel hypoplasia 0 (0)
Dental findings not related to tetracyclines, n (%)
molar incisor hypomineralization 7 (18)
unspecified developmental dental defects 5 (13)
fluorosis-like hypomineralization 3 (8)
Permanent teeth erupted, n (%) 22 (58)
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treated with doxycycline before the age of 8 years. The combined
prevalence of permanent tooth staining is 0/127. There is one re-
ported case of slight spotted discolouration of one deciduous tooth
after doxycycline use in a prematurely born infant ,2 months of
age.4 Considering that permanent teeth show less tetracycline ef-
fect than primary teeth,12 data on possible discolouration of per-
manent teeth are lacking.
The antibacterial spectrum of doxycycline includes Gram-
positive and Gram-negative bacteria. Both in vitro and in vivo activ-
ity is noted against atypical respiratory pathogens, Rickettsia and
many uncommon organisms. Doxycycline has a myriad of labelled
clinical indications.13 Many of our patients suffered from borrelio-
sis, which is common in South-West Finland. Doxycycline has been
shown to be as effective as ceftriaxone in the treatment of borre-
liosis.7 Doxycycline’s benefits are efficient oral administration and
effective blood–brain barrier penetration.14 It is of interest that
doxycycline may have neuroprotective properties in the treatment
of CNS infections, but clinical data are lacking.15
Our study has limitations. The study population was limited and
only two children were treated before the age of 1 year. In infants
the probability of side effects is larger, limiting the generalization
of the findings. Only visible effects (discolouration and enamel
hypoplasia) of permanent teeth were evaluated as these findings
were considered the most relevant. In addition, the dental exam-
ination was performed at the phase of mixed dentition in one-
third of patients, so the absence of staining in posterior molars
cannot be excluded. However, we see possible discolouration in
posterior molar teeth cosmetically as irrelevant because these
teeth are only visible at dental examination.
The strength of this study is the clinical relevance of the end-
point: visible staining of the permanent teeth. This was examined
by two independent experienced paediatric dentists with similar
results. This is the first study on the safety of intravenous, high-
dose or long doxycycline treatment in children.
In conclusion, our observations and those of others suggest
that the age limit of 8 years in the use of doxycycline should be re-
considered. Doxycycline would be a very useful antibiotic in young
children. It is inexpensive and could have wide use in developing
countries.
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